https://www.selleckchem.com/pr....oducts/k-ras-g12c-in
The mid-dose pUDK-HGF (6 mg) was the most efficacious, and is therefore an appropriate dose for use in a phase III clinical trial. This study was approved by the China Food and Drug Administration (2013L00637), China Clinical Trial Registry URL www.chinadrugtrials.org.cn. Unique Identifier 20130378.Background Systemic treatment of rheumatoid arthritis has been accompanied with several side effects. This study attempts to reduce leflunomide systemic side effects besides increasing its joint healing outcomes via formulation
Like
Comment
Share
